COVID-19: Takeda Pharmaceutical, immunoglobulin clinical trial started: 500 participants from 18 countries
Takeda:
-A coalition of 13 domestic and foreign pharmaceutical companies-
On October 9, it announced that it had begun clinical trials of “advanced immunoglobulin preparations.”
“Highly immunoglobulin preparation”:
It is made by concentrating and purifying “antibodies of patients who have recovered from the new coronavirus infection”.
500 people from 18 countries, including Japan, will participate in the clinical trial.
In clinical trials:
Patients requiring hospitalization were randomly divided into two groups
On one side, in addition to the antiviral drug remdesivir, a single infusion of the preparation,
The other group was given remdesivir and a placebo with no medicinal properties.
Investigate whether it is effective in preventing aggravation.
Asahi Shimbun Digital
https://www.asahi.com/articles/ASNB95SF2NB9PLZU001.html
First Patient Enrolled in NIH Phase 3 Trial to Evaluate Potential COVID-19 Hyperimmune Medicine
The Alliance’s anti-COVID-19 Hyperimmune Globulin (CoVIg-19) medicine
is under evaluation as part of the trial and may become one of the earliest treatments for hospitalized individuals at risk for serious complications of COVID-19
The CoVIg-19 Plasma Alliance
urges anyone who has recovered from COVID-19 to consider donating plasma.
The CoVIg-19 Plasma Alliance,
an unprecedented collaboration of leading plasma companies supported by global organizations outside the plasma industry,
today confirmed that patients are now being enrolled in the Inpatient Treatment with Anti-Coronavirus Immunoglobulin (ITAC) Phase 3 clinical trial sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).
The trial will evaluate the safety, tolerability and efficacy of an investigational anti-coronavirus hyperimmune intravenous immunoglobulin (H-Ig) medicine for treating hospitalized adults at risk for serious complications of COVID-19 disease.
If successful, the Alliance’s H-Ig may become one of the earliest treatment options for hospitalized COVID-19 patients.